Meeting Coverage

Biomarker tests for non-small lung cancer (NSCLC) improve patient outcomes, but they are not available to everyone.

Researchers evaluated whether targeted next-generation sequencing was comparable to fluorescence in situ hybridization for detecting genetic alterations in CLL.

Adding BCR kinase inhibitor ibrutinib or idelalisib to monoclonal antibody pembrolizumab increases treatment efficacy in CLL with Richter transformation.

Black patients with HCC are less likely than White patients to receive curative treatment.

High-dose melphalan conditioning confers survival benefits in patients with extramedullary and non-extramedullary multiple myeloma.

African Americans benefit from targeted multiple myeloma interventions.

AI detects lung cancer better than humans do.

While patients with hepatocellular carcinoma largely felt independent, their caregivers reported burdens related to appointment logistics and emotional support.

Researchers at the 2024 ASCO Annual Meeting studied the rapid titration of venetoclax for chronic lymphocytic leukemia and mantle cell lymphoma.

Patients with multiple myeloma who were admitted for gastrointestinal bleeding had higher costs and mortality than those without multiple myeloma.

Ultrasensitive Circulating Tumor DNA improves clinical sensitivity of minimal residual disease in early stage non-small cell lung cancer.

HCC survival time is predicted by albumin-bilirubin grade, microvascular invasion, and distant metastases.

Social determinants of health create barriers that delay access to expensive oral anti-myeloma drugs for people with newly diagnosed multiple myeloma.

AI and ML advances chronic lymphocytic leukemia therapies.